Patent 7429667 was granted and assigned to Ardea Biosciences, Inc. on September, 2008 by the United States Patent and Trademark Office.
The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.